Using the NPS treatment, patients will be able to leave the hospital and return to their jobs and to normal lives, said Nader, which makes the cost of the treatment not only invaluable to patients, but also a great savings for insurance providers.
Nader noted that a full 100% of patients surveyed said they were interested in trying the drug and NPS even has a program in place to help patients with their co-pays if they have them. Nader said that no patient will be denied this treatment for a lack of the ability to pay.
Cramer said that while some may scoff at the thought of a $300,000 a year drug, clearly it is far better than the alternative, which is why orphan-drug makers like NPS are so critical to our health-care system. He once again recommended the stock of NPS Pharmaceuticals.
It's playoff season, Cramer told viewers, and that means the best football teams square off against each other. But it's also time to put the top-performing stocks against each other.
That's why he looked at
(HD - Get Report)
Bank of America
(BAC - Get Report)
, two of the top-performing Dow stocks last year, to see which one makes the grade for 2013.
Cramer said both companies are excellent and both will see their share prices head higher in 2013, but Home Depot is the quintessential "A" student that just keeps on delivering more "A's." Bank of America, however, was a "C-" student that's been hitting the books and is now a solid "B" student now that Wall Street is starting to notice and reward.
Bank of America needs a healthy economy in order to recover, noted Cramer. Fortunately, the U.S. economy is starting to deliver with stronger housing, autos and maybe even job growth soon.
Many of the worries for this sector are now behind it. Bank of America, in particular, has taken out huge costs, cleaned up its balance sheet and is receiving approvals to return more capital to shareholders. Shares of Bank of America may be up 109% for 2012, but it still trades at a 30% discount to its tangible book value, said Cramer.